We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

Fund managers haven’t disclosed any holdings of ABOS yet.

ABOS Hedge Fund Activity: Q1 2026 in Review

84 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2026, worth a combined $109M — up 44% from $75.2M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABOS positions and 7 closed out — a net gain of 14 holders — while 31 added to existing stakes and 12 trimmed.

The largest buyer was RA Capital Management, adding an estimated $15.5M. The largest seller was Fidelity Investments, cutting an estimated $2.22M.

  • 84 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2026, up from 71 in Q4 2025.
  • Funds reported $109M of Acumen Pharmaceuticals stock for Q1 2026, up 44% quarter-over-quarter.
  • 21 funds opened new Acumen Pharmaceuticals positions in Q1 2026 and 7 closed out, a net change of +14 holders.
  • The largest Acumen Pharmaceuticals buyer in Q1 2026 was RA Capital Management, an estimated $15.5M added.
  • The largest Acumen Pharmaceuticals seller in Q1 2026 was Fidelity Investments, an estimated $2.22M sold.

Based on aggregated 13F filings for Q1 2026.